Abbott India Ltd

₹26,758.85▼ -0.66%28 Sept

📊 Stock Analysis

Market Data

Market Cap₹56,860.69 Cr.

52W High₹30,598

Current Price₹26,758.85

52W Low₹25,140.5

Down from 52W High12.5 %

Face Value₹10

Performance

ROCE45.73 %

ROE33.82 %

EPS (TTM)₹201.66

EPS Prev Qtr₹185.85

EPS Last Year₹195.42

EBITDA Qtr₹502.75 Cr.

Book Value₹2,247

Financial Health

Debt/Equity0

Debt/Profit0

Total Assets₹6,501.93 Cr.

Dividend Yield1.78 %

Promoter Holding74.99 %

Earning Power29.11 %

Valuation

Stock P/E35.22

Industry P/E33.81

Price to Book11.91

Price to Sales8.12

Graham Number₹6,197.74

Key Metrics

__derived

Face Value

₹10

About Abbott India Ltd

Healthcare · Pharmaceuticals

Abbott India Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹56,860.69 Cr.

Price Chart

Strengths & Weaknesses

Strengths

The company has a high ROCE of 45.73%, indicating efficient use of capital.
The company boasts a strong ROE of 33.82%, reflecting profitability relative to shareholder equity.
The company is debt-free with a Debt to Equity ratio of 0, reducing financial risk.
The company has a significant promoter holding of 74.99%, suggesting strong management control.

Weaknesses

The P/E ratio of 33.67 suggests that the stock may be overvalued relative to earnings.
The P/B ratio of 11.39 indicates that the market values the company at a premium over its book value.
The dividend yield is relatively low at 1.86%, which may not attract income-focused investors.

Peer Comparison

Name	CMP	P/E	Market Cap	Div Yield	NP Qtr	Qtr Profit Var%	Sales Qtr	Qtr Sales Var%	ROCE%	Debt/Eq
Sun Pharmaceutical Industries Ltd	-	36.51	₹4,41,477.63 Cr	0.87%	₹12,172.7 Cr	-	₹59,910.52 Cr	-	18.72%	0.05
Divis Laboratories Ltd	-	86.48	₹2,53,031.38 Cr	0.31%	₹2,925 Cr	-	₹11,230 Cr	-	23.04%	0
Torrent Pharmaceuticals Ltd	-	77.67	₹1,85,216.32 Cr	0.78%	₹2,156 Cr	-	₹15,723 Cr	-	15.1%	1.76
Zydus Lifesciences Ltd	-	27.01	₹1,20,897.46 Cr	0.08%	₹4,492.2 Cr	-	₹28,591.7 Cr	-	16.76%	0.43
Cipla Ltd	-	33.28	₹1,12,201.64 Cr	0.94%	₹3,364.84 Cr	-	₹28,324.4 Cr	-	13.24%	0.01
Laurus Labs Ltd	-	99.31	₹1,08,698.22 Cr	0.06%	₹1,090.76 Cr	-	₹7,269.64 Cr	-	20.79%	0.45
Dr Reddys Laboratories Ltd	-	31.6	₹1,02,039.12 Cr	0.65%	₹3,183.3 Cr	-	₹33,227.9 Cr	-	10.05%	0.17
Mankind Pharma Ltd	-	49.29	₹1,00,752.43 Cr	0.04%	₹2,067.57 Cr	-	₹14,737.88 Cr	-	13.95%	0.38
Aurobindo Pharma Ltd	-	26.56	₹97,814.24 Cr	0.24%	₹3,710.8 Cr	-	₹34,935.29 Cr	-	12.75%	0.2
Lupin Ltd	-	16.64	₹94,274.49 Cr	0.87%	₹5,550.99 Cr	-	₹29,966.58 Cr	-	27.95%	0.26
Glenmark Pharmaceuticals Ltd	-	36.67	₹65,922.11 Cr	0.11%	₹1,797.81 Cr	-	₹17,736.56 Cr	-	24.78%	0.25
Alkem Laboratories Ltd	-	28.65	₹61,804.34 Cr	1.03%	₹2,206.3 Cr	-	₹15,081.28 Cr	-	19.75%	0.12
Biocon Ltd	-	110.29	₹61,113.53 Cr	0.13%	₹416.4 Cr	-	₹17,321.1 Cr	-	2.87%	0.43
Abbott India Ltd	-	35.22	₹56,860.69 Cr	1.78%	₹1,614.68 Cr	-	₹7,004.38 Cr	-	45.73%	0
Glaxosmithkline Pharmaceuticals Ltd	-	46.73	₹49,091.33 Cr	1.97%	₹1,068.15 Cr	-	₹3,954.94 Cr	-	64.07%	0
Ipca Laboratories Ltd	-	36.13	₹48,712.48 Cr	0.31%	₹1,379.76 Cr	-	₹10,125.58 Cr	-	21.48%	0.09
Anthem Biosciences Ltd	-	83.03	₹47,949.68 Cr	0.23%	₹575.95 Cr	-	₹2,002.34 Cr	-	25.5%	0.02
Gland Pharma Ltd	-	42.26	₹47,764.08 Cr	0.69%	₹1,128.8 Cr	-	₹6,725.3 Cr	-	15.21%	0.02
Ajanta Pharma Ltd	-	38.87	₹44,109.77 Cr	0.79%	₹1,134.88 Cr	-	₹5,776.17 Cr	-	31.81%	0.05
J B Chemicals & Pharmaceuticals Ltd	-	53.3	₹38,730.77 Cr	0.39%	₹709.46 Cr	-	₹4,147.79 Cr	-	23.03%	0

Quarterly Results

📊 Jun 2026: Revenue grew 4.3% YoY, Profit grew 17.1% YoY

	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,738.35	1,757.15	1,724.04	1,709.51	1,813.68
↳ QoQ Growth	-	+1.1%	-1.9%	-0.8%	+6.1%
Expenses	1,312.24	1,273.62	1,279.34	1,247.73	1,310.93
Operating Profit	426.11	483.53	444.7	461.78	502.75
OPM %	24.51%	27.52%	25.79%	27.01%	27.72%
Other Income	72.84	69.95	69.76	75.59	75.37
Interest	5.82	7.55	5.48	6.14	5.91
Depreciation	19.48	18.64	18.77	19.07	19.75
EBITDA	445.59	502.17	463.47	480.85	522.5
EBITDA Margin %	25.63%	28.58%	26.88%	28.13%	28.81%
Profit Before Tax	493.13	545.93	508.98	531.23	572.21
Tax %	25.81%	23.93%	26.13%	25.66%	25.11%
Net Profit	365.86	415.27	375.96	394.93	428.52
↳ QoQ Growth	-	+13.5%	-9.5%	+5.0%	+8.5%
EPS	172.17	195.42	176.92	185.85	201.66

Profit & Loss

	Mar 2026	TTM
Sales	6929.05	7004.38
Expenses	5112.93	5111.62
Operating Profit	1816.12	1892.76
OPM %	26.21%	27.02%
Other Income	288.14	290.67
Interest	24.99	25.08
Depreciation	75.96	76.23
Profit Before Tax	2079.27	2158.35
Tax %	25.36%	25.19%
Net Profit	1552.02	1614.68
EPS	730.36	759.85

Compounded Sales Growth

10Y

TTM

Compounded Profit Growth

10Y

TTM

Stock Price CAGR

10Y

-9.74%

Return on Equity

10Y

Last Year

33.82%

Balance Sheet

	Mar 2025	Mar 2026
Equity Capital	21.25	21.25
Reserves	4211.9	4752.94
Borrowings	196.67	0
Other Liabilities	1487.49	1727.74
Total Liabilities	5917.31	6501.93
Fixed Assets	329.52	331.32
CWIP	18.08	5.51
Investments	0	0
Other Assets	5569.71	6165.1
Total Assets	5917.31	6501.93

Cash Flows

	Mar 2026
Cash from Operating Activity	1319.24
Cash from Investing Activity	-371.38
Cash from Financing Activity	-1066.12
Net Cash Flow	-118.26

Ratios

	Mar 2026
Debtor Days	-
Inventory Days	-
Days Payable	-
Cash Conversion Cycle	-
Working Capital Days	342.5
ROCE %	27.93%

Shareholding Pattern

	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters %	74.99%	74.99%	74.99%	74.99%
FIIs %	0.16%	0.18%	0.26%	0.38%
DIIs %	9.11%	9%	8.93%	8.78%
Public %	13.43%	13.42%	13.38%	13.41%
No. of Shareholders	71,199	75,801	75,866	78,320

Major Shareholders (>1%)

As of 2026-06-30View all shareholders →

Tools